MEMPHIS, Tenn., March 2 /PRNewswire-USNewswire/ -- Accelerated Community Oncology Research Network (ACORN(TM)), an oncology focused research network, announced today the highlights of its annual Principal Investigators' Meeting held in Scottsdale, AZ in February. Medical oncologists from community-based oncology practices throughout the United States met to discuss the latest cancer research advances, emerging treatment trends, as well as promising new molecules in the drug pipeline.
2008 represented a banner year for ACORN and its network members. 74 different sponsors, representing 93 industry-sponsored trials, engaged the ACORN Network. Additionally, 21 ACORN investigator initiated trials were open in 2008. The ACORN portfolio included studies of 41 different investigational agents in 2008. 62% of ACORN's 2008 studies were Phase II with the majority of the trials focusing on cancers of the lung, breast, ovary, colon/rectum, or pancreas. ACORN also delivered research opportunities for less frequently seen cancers to its member practices to make treatments of all cancer types available.
"Commitment to research excellence is integral to the ACORN process as is thorough education of all staff members. We continue to identify new processes to facilitate rapid deployment of clinical trials to community-based oncology practices while experiencing banner growth," remarked Edward J. Stepanski, PhD, COO, ACORN.
Practicing oncologists in the ACORN Network serve as Tumor Committee Chairs. Those presenting at the 2009 Meeting included Mark Keaton, MD, Augusta Oncology Associates, Augusta, GA, Gastroenterology; Lee Schwartzberg, MD, FACP, The West Clinic, Memphis, TN, Breast Cancer; Frederick Schnell, MD, FACP, Central Georgia Cancer Care, Macon, GA
|SOURCE Accelerated Community Oncology Research Network, Inc.|
Copyright©2009 PR Newswire.
All rights reserved